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RESUMEN
Objetivo: La vía oral siempre ha sido la ruta preferida de administración de fármacos en muchas enfer-
medades y hasta hoy es la primera forma investigada en el desarrollo de nuevas formas de dosificación. 
El principal problema en las formulaciones de fármacos orales es la baja y errática biodisponibilidad, lo 
que resulta fundamentalmente por la escasa solubilidad en agua, con lo que plantean problemas en su 
formulación. Para la administración terapéutica de los grupos activos lipófilos (BCS clase II drogas), las 
formulaciones a base de lípidos están teniendo cada vez más atención.
Métodos: Con ese objetivo, a partir de los sitios web de PubMed, HCAplus, Thomson, y sus registros se 
utilizaron como fuentes principales para llevar a cabo la búsqueda de los artículos de investigación más 
importantes publicados sobre el tema. A continuación, la información fue analizada cuidadosamente, 
poniendo de relieve los resultados más importantes en la formulación y desarrollo de sistemas de admi-
nistración de fármacos auto-emulsionante micro, así como su actividad terapéutica.
Resultados: El sistema de administración de fármacos autoemulsionante (SMEDDS) ha ganado más 
atención debido a la mejorada que permite la reducción de la biodisponibilidad oral en dosis, los perfiles 
temporales más consistentes de la absorción del fármaco, la orientación selectiva de fármaco (s) hacia 
la ventana de absorción específica en el tracto gastrointestinal, y la protección del fármaco (s) desde el 
entorno poco receptivo en el intestino.
Conclusiones: Este artículo proporciona una visión completa de SMEDDS como un enfoque prometedor 
para abordar eficazmente el problema de moléculas poco solubles.
Palabras clave: SMEDDS; tensioactivo; aceite; cosurfactante; biodisponibilidad.
ABSTRACT
Aim: Oral route has always been the favorite route of drug administration in many diseases and till 
today it is the first way investigated in the development of new dosage forms. The major problem in oral 
drug formulations is low and erratic bioavailability, which mainly results from poor aqueous solubility, 
thereby pose problems in their formulation. For the therapeutic delivery of lipophilic active moieties 
(BCS class II drugs), lipid based formulations are inviting increasing attention.
Methods: To that aim, from the web sites of PubMed, HCAplus, Thomson, and Registry were used as the 
main sources to perform the search for the most significant research articles published on the subject. The 
information was then carefully analyzed, highlighting the most important results in the formulation and 
development of self-micro emulsifying drug delivery systems as well as its therapeutic activity.
Results: Self-emulsifying drug delivery system (SMEDDS) has gained more attention due to enhanced 
oral bio-availability enabling reduction in dose, more consistent temporal profiles of drug absorption, 
selective targeting of drug(s) toward specific absorption window in GIT, and protection of drug(s) from 
the unreceptive environment in gut.
Conclusions: This article gives a complete overview of SMEDDS as a promising approach to effectively 
deal with the problem of poorly soluble molecules.
Keywords: SMEDDS; surfactant; oil; co-surfactant; bioavailability.
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INTRODUCTION TO LIPID-BASED FORMULA-
TIONS
Successful oral delivery of drugs has always remained a 
challenge to the drug delivery field, since approximately 
40% of the new drug candidates have poor water solubility, 
and thus oral delivery is frequently associated with impli-
cations of low bioavailability. Many approaches have been 
meticulously explored to improve the oral bioavailability of 
such drugs including particle size reduction (micronization 
or nanosizing), complexation with cyclodextrins, salt for-
mation, solubilization based on cosolvents, surfactants, etc. 
Modification of the physicochemical properties, such as by 
salt formation and particle size reduction of the drug may 
improve the dissolution rate of the drug but these meth-
ods are not always practical, for example, salt formation of 
neutral compounds is not feasible. Moreover, the salts of 
weak acid and weak base may convert back to their origi-
nal acid or base forms and lead to aggregation in the gas-
trointestinal tract. Particle size reduction may lead to build 
up of static charges, present handling difficulties and is not 
desirable where poor wettability are experienced for very 
fine powders. To overcome these limitations, various other 
formulation strategies have been attempted such as use 
of cyclodextrins, nanoparticles, solid dispersions and per-
meation enhancers. Indeed, in some selected cases, these 
approaches have been successful.1 Of late lipid-based for-
mulations have attracted great deal of attention to improve 
the oral bioavailability of poorly water soluble drugs. In 
fact, the most favored approach is to incorporate lipophilic 
drugs into inert lipid vehicles such as oils, surfactant dis-
persions, micro emulsions, self-emulsifying formulations, 
self-micro emulsifying formulations, and liposomes. This 
could lead to increased solubilisation with concomitant 
modification of their pharmacokinetic profiles, leading to 
increase in therapeutic efficacy. 1
Lipid based formulations offer a wide variety of formula-
tions like solutions, suspensions, solid dispersions and self-
micro emulsifying drug delivery systems (SMEDDS). 2 The 
SMEDDS have attracted considerable interest after com-
mercial success of immunosuppressive agent cyclosporine 
A (Neoral®) and the two HIV protease inhibitor ritonavir 
(Norvir®) and saquinavir (Fortovase®). Self- emulsifying 
formulations comprise isotropic mixtures of natural or syn-
thetic oils with lipophilic or hydrophilic surfactants and 
co-solvents which spontaneously emulsify when exposed 
to the fluids of the gastrointestinal tract (GIT) to form oil-
in-water emulsion or micro emulsion. The SMEDDS offer 
following advantages:
 – Thermodynamic steadiness. 3
 – Enhanced solubilization of bioactive substances. 3
 – Improvement in oral bioavailability by increasing solu-
bility and efficient drug transport. 3
 – Improved patient compliance.
 – Reduced dosing frequency.
 – Ease of manufacture and scale-up as compare to other 
lipid dosage forms. 4
 – Reduction in inter-subject and intra-subject variability 
and food effects.3, 4
 – Ability to deliver active biomolecules including peptides 
that are sensitive towards enzymatic hydrolysis in GIT. 3
 – No influence of lipid digestion process unlike the other 
lipid-based drug delivery systems. 5, 6
 – When polymer is incorporated in composition of 
SMEDDS it gives prolonged release of medicament.
The lipidic systems provide the abovementioned merits, 
however, this suffers from pit falls as under: 3, 4
1. Lack of good predicative in vitro models for assessment 
of the formulations.
2. This in vitro model needs further development and vali-
dation before its strength can be evaluated.
3. Further development will be based on in vitro - in vivo 
correlations and therefore different prototype lipid 
based formulations needs to be developed and tested in 
vivo in a suitable animal model.
4. Another is chemical instabilities of drugs and high sur-
factant concentrations in formulations (approximately 
30-60%) which irritate GIT.
Classification System for Lipid Formulations
The lipid formulation classification system was first in-
troduced in 2000 and the extra ‘type’ of formulation was 
added in 2006.7
Type I - These systems shows poor initial aqueous disper-
sion and require digestion by pancreatic lipase/co-lipase 
in GIT to produce more amphiphilic lipid digestion prod-
ucts and promote drug transfer into the colloidal aqueous 
phase. These are a good option for drugs having sufficient 
solubility in oils. Valproic acid has been formulated in soft 
gelatine capsules containing corn oil as lipidic component. 7
Type II - Type II lipid formulations constitute SEDDS. 
Self-emulsification is generally obtained at surfactant con-
tent above 25% (w/w). These formulations provide the 
advantage of overcoming the slow dissolution step typi-
cally observed with solid dosage forms and as described 
above generate large interfacial areas which in turn allows 
efficient partitioning of drug between oil droplets and the 
aqueous phase from where absorption occurs. 7,8
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Type III - Type III lipid based formulations, commonly re-
ferred to as self-micro emulsifying drug delivery systems 
(SMEDDS), are defined by inclusion of hydrophilic sur-
factant (HLB > 12) and co-solvent such as ethanol, poly 
ethylene glycol and propylene glycol. Type III formulation 
can be further segregated into type IIIA and type IIIB for-
mulations in order to identify more hydrophilic systems 
(type IIIB) where the content of hydrophilic surfactant and 
co-surfactant increases and the lipid content reduces. Type 
IIIB formulations typically achieve greater dispersion rates 
when compared to type IIIA although the drug precipita-
tion risk on dispersion of the formulation is higher given 
the lower lipid content. 7
Type IV- These formulations commonly offer increased 
drug payloads when compared to the formulations con-
taining simple glycerides lipids and also produce very fine 
dispersion when introduce in aqueous An example of type 
IV formulation is the current capsule formulation of the 
HIV protease inhibitor Amprenavir (Agenerase®) which 
contains TGPS as a surfactant and PEG 400 and PG as a 
cosolvent. 7
MECHANISM OF SELF-MICRON EMULSIFICATION
According to Reiss, the energy required to increase the 
surface area of the dispersion for self-emulsification pro-
cess bear less importance when compared to the entropy 
change that favours dispersion. Self- micron emulsifying 
process is related to the free energy. 9 That is free energy of 
the conventional emulsion is a direct function of the energy 
essential to create a new surface between the oil and water 
phases and can be described by the equation:
DG=S N p r 2s
Where, DG is the free energy related to the process, N is 
the number of droplets of radius r and s represents the 
interfacial energy. The emulsion is stabilized by emulsify-
ing agents only after the two phases of emulsion is sepa-
rated with respect to time to reduce the interfacial area. The 
emulsifying agent forms a monolayer of emulsion droplets, 
and hence reduces the interfacial energy, and providing 
a barrier to avoid coalescence. In the case of self-micron 
emulsifying systems, the free energy required to form the 
emulsion is either very low or positive, or negative.10 Emul-
sification requires very little input energy involves destabi-
lization through contraction of local interfacial region.
Phase Diagrams
The microemulsion region is usually characterized by 
constructing ternary-phase diagrams. Three components 
are the basic requirement to form a microemulsion: an oil 
phase, an aqueous phase and a surfactant. If a co-surfactant 
is used, it may sometimes be represented at a fixed ratio to 
surfactant as a single component, and treated as a single 
«pseudo-component». The relative amounts of these three 
components can be represented in a ternary phase diagram. 
Gibbs phase diagrams can be used to show the influence of 
changes in the volume fractions of the different phases on 
the phase behaviour of the system. The three components 
composing the system are each found at an apex of the tri-
angle, where their corresponding volume fraction is 100 %. 
Moving away from that corner reduces the volume fraction 
of that specific component and increases the volume frac-
tion of one or both of the two other components. Each point 
within the triangle represents a possible composition of a 
mixture of the three components or pseudo-components, 
which may consist (ideally, according to the Gibbs’ phase 
rule) of one, two or three phases. These points combine to 
form regions with boundaries between them, which repre-
sent the «phase behaviour» of the system at constant tem-
perature and pressure.
The Gibbs phase diagram, however, is an empirical visual 
observation of the state of the system and may, or may not 
express the true number of phases within a given composi-
tion. Apparently clear single phase formulations can still 
consist of multiple iso-tropic phases (e.g. the apparently 
clear heptane/ Sodium bis (2-ethylhexyl) sulfosuccinate 
(AOT)/water microemulsions consists of multiple phas-
es). Since these systems can be in equilibrium with other 
phases, many systems, especially those with high volume 
fractions of both the two immiscible phases, can be eas-
ily destabilised by anything that changes this equilibrium 
e.g. high or low temperature or addition of surface tension 
modifying agents. However, examples of relatively stable 
microemulsions can be found. It is believed that the mecha-
nism for removing acid build up in car engine oils involves 
low water phase volume, water-in-oil (w/o) microemul-
sions. Theoretically, transport of the aqueous acid droplets 
through the engine oil to microdispersed calcium carbonate 
particles in the oil should be most efficient when the drop-
lets are small enough to transport a single hydrogen ion 
(the smaller the droplets, the greater the number of drop-
lets, the faster the neutralisation). Such microemulsions are 
probably very stable across a reasonably wide range of el-
evated temperature. 11
FORMULATION OF SMEDDS
Upon dilution, the SMEDDS formulation immediately 
forms a clear dispersion and remains stable (Fig.1). The 
hydrophobic drug dispersed in the SMEDDS formulation 
remains solubilized it is absorbed. Efficient release of the 
drug from the formulation mainly depends on two factors, 
globule size and polarity of the droplets. In case of oil-in-
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water microemulsions, the polarities of oil droplets are not 
considerable, since the drug incorporated in the oil glob-
ules reach the capillaries. 12,13
The following parameters must be considered during the 
formulation of SMEDDS:
1. Solubility of the drug in different oil, surfactants and co-
solvents.
2. Selection of oil, surfactant and cosolvent based on the 
solubility of the drug, and preparation of the phase dia-
gram.
  
Fig. 1. Flow chart for preparation of SMEDDS 
Selection of suitable drug candidate
Lipid based formulations offer a potential platform for 
improving oral bioavailability of drugs specially those 
belonging to Biopharmaceutical Classifi cation System 
(BCS) class II and class IV. A primary indication of the po-
tential utility of lipid based formulation can be obtained 
by assessing the drug lipophilicity (log P) and its solubil-
ity in pharmaceutically-acceptable lipid excipients, which 
should be suffi cient to allow the entire dose of the drug to 
be administered in a single dosage unit. Another indicator 
of the potential for success of lipid based formulation is the 
observance of a strong positive food effect when the drug 
is administered with a fatty meal as opposed to dosing in 
the fasted.14 For lipophilic drug compounds that exhibit 
dissolution dissolution-rate-limited absorption, SMEDDS 
can offer an improvement in rate and extent of absorption 
resulting in reproducible blood time profi le. The systems 
SMEDDS usually provide advantage of increased drug 
loading capacity when compared with lipid solutions as the 
solubility of poorly water soluble drugs with intermediate 
partition coeffi cient (2<log P<4) are typically low in natural 
lipids and much greater in amphiphilic surfactants, co-sur-
factants and co-solvents.2 The partition coeffi cient (log P) is 
the prime criterion of designing lipid based systems. High 
log P (greater than 4) is desirable for lipidic systems. Next 
physicochemical criteria that play an important role are 
melting point and dose. Low melting point and low dose 
are desirable for development of lipidic systems (Table 1).
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Composition of SMEDDS
SMEDDS formulations mainly comprise of the following 
substances:
a) Lipids (Oils)
Lipids are the important component of SMEDDS, as solubi-
lization and access of the drug to the lymphatic circulation 
of poor water soluble drugs depend on the type and con-
centration of oil used in the formulation. Digestive lipids 
such as triglycerides, diglycerides, fatty acids, phospholip-
ids, cholesterol and other lipids based on synthetic origin 
offer improvement in bioavailability of the drug in contrast 
to the non-digestible lipids with which reduced bioavail-
ability may occur due to impairment in absorption caused 
by retention of the fraction of administered drug in the for-
mulation itself. Lipids are generally insoluble in water and 
are often identified by their fatty acid composition, melting 
point, Hydrophilic-Lipophilic Balance (HLB), and solubil-
ity in non-polar organic solvents.15,16 Lipids with low HLB 
and high melting point are suitable for sustained release. 
Semi-solid excipients and those with high HLB serve as 
immediate release and bioavailability enhancement excipi-
ents. Lipid based excipients include dietary oils composed 
of medium (palm seed oil or coconut oil) or long chain tri-
glycerides (corn, olive, peanut, sesame oil).
b) Surfactants
Selection of a surfactant is mainly governed by the follow-
ing two factors: HLB and safety. In order to achieve high 
emulsifying property, the emulsifier used in SMEDDS for-
Table 1. Applications of SMEDDS relevant to BCS Classification
BCS class Aqueous solubility Membrane permeability Hurdles overcome by SMEDDS
I High High
Enzymatic degradation, Gut wall 
efflux
II Low High Solubilization, Bioavailability
III High Low
Enzymatic degradation, Gut wall 
efflux, Bioavailability
IV Low Low
Solubilization Enzymatic degrada-
tion, Gut wall efflux Bioavail-
ability
mulation should have high HLB and high hydrophilicity. 
This ensures immediate formation of oil-in-water droplets 
and rapid dispersion of formulation in aqueous media (e.g. 
gastrointestinal fluid). The drug dispersed in the SMEDDS 
formulation would remain solubilized for a prolonged pe-
riod of time at site of absorption for efficient absorption, 
thus preventing precipitation of drug compound within 
GI lumen.17 Non-ionic surfactants are most widely recom-
mended as they possess relatively high HLB value. Con-
centration of surfactant ranging in between 30% and 60% 
w/w form stable SMEDDS. Pharmaceutically acceptable 
surfactants include Cremophor® EL, Cremophor® RH40, 
Cremophor® RH60, polysorbate 80, various grades of ge-
lucires, etc.
c) Co-surfactants
Pharmaceutically acceptable co-surfactants include poly-
ethylene glycol 400, ethanol, propylene glycol. Lipid solu-
ble solvents are used in the formulation of SMEDDS as they 
enable dissolution of large quantities of hydrophilic sur-
factants (Table 2). The lipid mixture with higher surfactant 
and co-surfactant: oil ratios lead to the formation of stable 
SMEDDS.18
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Table 2. Examples of typical excipients used in SMEDDS formulations
Trade Name Chemical Name HLB Regulatory Status 
LIPIDS 
Vegetable oil Long-chain TAG - Oral products, GRAS,FDA IIG 
Miglyol 812 
Medium- chain TAG caprylic/
capric TAG 
- Oral products, GRAS,FDA IIG
Tricaprylin Medium-chain TAG - - 
Labrafac CC Caprylic/capric TG - - 
Ethyl oleate Ethyl ester of 18:1 FA - FDA IIG 
Captex 355 Glycerol caprylate caprate - GRAS,FDA IIG 
Isopropyl mysistate FA ester - FDA IIG 
Labrafac PG PG dicaprylocaprate - USFA,JSFA,EP 
Peceol Glyceryl mono-oleate 3.3 GRAS,E47,1EP,USP-NF,FDA IIG 
Maisine 35-1 Glyceryl mono-linoleate 4 Oral products,GRAS,EP,USP-NF,E471 
Imwitor 988 Caprylic/capric glycerides 3.8 USP,Ph.Eur 
Akoline MCM Caprylic/capric glycerides 5-6 - 
Surfactants HLB<12 
Tween 85 
Polyoxyethylene (20) sorbitan 
trioleate 
11 UK 
Labrafil M1944CS Oleoyl macrogolglycerdies 4 EP,FDA IIG,USP- NF 
Labrafil M2125CS Linoleoyl macrogolglycerides 4 EP,FDA IIG,USP- NF 
Lauroglycol 90 PG monolaurate 5 USFA,FCC,EFA,USP-NF 
Surfactants HLB>12 
Vitamin E TPGS 
D-alpha-tocopheryl PEG 1000 
succinate 
13 Oral products 
Cremophor EL Polyoxyl 35 castor oil 12-14 Oral products,USP-NF,FDA IIG 
Cremophor RH 40 
Polyoxyl 40 hydrogenated cas-
tor oil
14-16 Oral products,USP-NF,FDA IIG
Gelucire 44/14 Lauroyl macrogolglycerides 14 EP,USP-NF,FDA IIG 
Labrasol 
Caprylocaproyl macrogol 
glycerides 
14 EP,USP-NF,FDA IIG 
Polysorbate 80/Tween 80 
Polyoxyethylene (20) sorbitan 
monooleate 
15 Oral products,GRAS,EP,USP-NF,FD A IIG 
Polysorbate 20/Tween 20 
Polyoxyethylene (20) sorbitan 
monolaurate 
16.7 Oral products,GRAS,EP,USP-NF,FDA IIG 
Co-solvents 
Ethanol - - Oral products,EP,USP-NF 
PEG PEG 300 and PEG 400 - Oral products,EP,USP-NF 
Transcutol P Diethyl glycol monoethyl ether - EP,FDA IIG 
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CHARACTERISATION OF SMEDDS
Differential Scanning Calorimetry
Differential scanning calorimetry for SMEDDS can be de-
termined using DSC 60.Liquid sample and solid sample 
should be placed in aluminium pan and result can be re-
corded. The deviation from established thermal behavior 
could be determined by using DSC. This might be helpful 
to provide an idea about possible drug-excipient interac-
tions.
Fourier transform-infrared spectroscopy
Fourier transform-infrared for SMEDDS can be determined 
using FT-IR. Liquid sample should be placed in the liq-
uid sample holder and result can be recorded. This tech-
nique enables the researchers to find out presence of newly 
formed bonds between functional groups present in drug 
as well as selected excipients.
Macroscopic evaluation
Macroscopic evaluation analysis is carried out in order to 
observe the homogeneity of micro emulsion formulations. 
Any change in color and transparency or phase separation 
occurring during normal storage condition (37±2°C) is ob-
served in optimized micro emulsion formulation. The uni-
formity of globule size ensures adequate drug distribution 
in the formulation.
Visual assessment
To assess the self-emulsification properties, formulation is 
introduced into 100 ml of water in a glass Erlenmeyer flask 
at 25°C and the contents were gently stirred manually. The 
tendency to spontaneously form a transparent emulsion is 
judged as good and it is judged bad when there is poor or 
no emulsion formation. Phase diagram is constructed iden-
tifying the good self-emulsifying region. The formation of 
transparent product may be taken as end point to declare 
accomplishment of preparation.
Determination of self-emulsification time
The emulsification time of SMEDDS is determined accord-
ing to USP 22; dissolution apparatus about 2 mg of each 
formulation are added drop wise to 500 ml purified water 
at 37°C. Gentle agitation is provided by a standard stainless 
steel dissolution paddle rotating at 50 rpm. Emulsification 
time is assessed visually. This gives the formulator infor-
mation regarding time lapsed during formulation.
Solubility studies
Unknown amount of selected vehicle is added to each cap 
vial containing an excess of drug, after sealing, the mixture 
is heated at 40°C in a water bath to facilitate the solubili-
zation. Mixing of the system is performed using a vortex 
mixer. Formed suspensions are then shaken with a shaker 
at 25°C for 48 hours. After reaching equilibrium, each vial is 
centrifuged at 3000 rpm for 5 minutes, and excess insoluble 
drug is discarded by filtration using a membrane filter. The 
concentration of drug is quantified by U.V. spectrophotom-
eter. The solubility is an important aspect while selection of 
excipients. Only the optimized selection of excipients may 
yield a transparent product.
Transmittance test
Stability of optimized micro emulsion formulation with 
respect to dilution is checked by measuring Transmittance 
through U.V. spectrophotometer (UV-1700 SHIMADZU), 
Transmittance of samples is measured at suitable wave-
lengths and for each sample three replicates assays were 
performed. This is done to see the impact of dilution on the 
prepared formulation.
Droplet size determination
It is a precise method for evaluation of stability the size of 
droplets is measured by photon-correlation spectroscopy 
(PSC) with Zetasizer. All measurements are carried out at 
scattering angle of 90°C and 25°C temperatures. Prior to 
measurement, microemulsion is diluted into two steps with 
pure water then it is filtered through a 0.22μm filter just 
before it is added to cuvette. At first it is diluted with equal 
amount of water. In second step the mixture if further dilut-
ed to appropriate concentration for the measurement. That 
depends on droplet size (usually diluted 100-200 times). 
The globule size measurement helps to maintain the size 
distribution in desired range. Any deviations from this call 
for further trials.
Zeta potential measurement
Zeta potential for micro emulsion is determined using 
Zetasizer HAS 3000. Samples are placed in clear disposable 
zeta cells and results are recorded. Before putting the fresh 
sample cuvettes are washed with the methanol and rinsed 
using the sample to be measured before each experiment. 
The zeta potential values represent the surface charge of 
the dispersed globules. The higher the value of zeta poten-
tial more the stability is. This may be because of repulsion 
caused by individual globules during random movements 
in the continuous medium.
Stability
Temperature Stability
Shelf life is a function of time and storage temperature is 
evaluated by visual inspection of the SMEDDS system at 
different time period. SMEDDS is diluted with purified 
water and to check the temperature stability of samples, 
they are kept at three different temperature range [2-8°C 
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(refrigerator), room temperature etc.] and observe for any 
evidence of phase separation, flocculation or precipitation 
so that an appropriate storage condition may be prescribed 
for the developed product.
Centrifugation
In order to estimate metastable system, the optimized 
SMEDDS formulation is diluted with purified distilled wa-
ter. Then micro emulsion is centrifuged at 1000 rpm for 15 
minute at 0°C and observed for any change in homogeneity 
of micro emulsions. This indicates the stability of product 
upon dilution.
In vitro drug release
The quantitative in vitro release test is performed in 900 ml 
purified distilled water, which is based on USP 24 method. 
SMEDDS is placed in dialysis bag during the release pe-
riod to compare the release profile with other pharmaceu-
tical dosage forms.10 ml of sample solution is withdrawn 
at predetermined time intervals, filtered through 0.45 μ 
membrane filter, dilute suitably and analyzed spectropho-
tometrically. Equal amount of fresh dissolution medium 
is replaced immediately after withdrawal of test sample. 
Percent drug dissolved at different time interval is calcu-
lated. The drug release studies are performed to assess the 
dissolution pattern of the formulation in selected medium. 
The drug release data are further subjected to various ki-
netic models such as zero order, first order, Korsemeyer, 
Higuchi’s equation etc. in order to determine mechanism 
of drug release.
SOLID SELF-MICRON EMULSIFYING DRUG DELIV-
ERY SYSTEMS (S-SMEDDS)
SMEDDS can exist in either liquid or solid states. SMEDDS 
are usually, however, limited to liquid dosage forms, be-
cause many excipients used in SMEDDS are not solids at 
room temperature. Given the advantages of solid dosage 
forms, S-SMEDDS have been extensively exploited in re-
cent years, as they frequently represent more effective alter-
natives to conventional liquid SMEDDS. From the perspec-
tive of dosage forms, S-SMEDDS mean solid dosage forms 
with self-emulsification properties. S-SMEDDS focus on 
the incorporation of liquid/semisolid SME ingredients into 
powders/nanoparticles by different solidification tech-
niques (e.g. adsorptions to solid carriers, spray drying, melt 
extrusion, nanoparticles technology, and so on). Such pow-
ders/nanoparticles, which refer to SE nanoparticles19 dry 
emulsions/solid dispersions, are usually further processed 
into other solid SE dosage forms, or, alternatively, filled into 
capsules (i.e. SME capsules). SME capsules also include 
those capsules into which liquid/semisolid SMEDDS are 
directly filled without any solidifying excipients. To some 
extent, S-SMEDDS are combinations of SMEDDS and solid 
dosage forms, so many properties of S-SMEDDS (e.g. ex-
cipients selection, specificity, and characterization) are the 
sum of the corresponding properties of both SMEDDS and 
solid dosage forms. For instance, the characterizations of 
SME pellets contain not only the assessment of self-emul-
sification, but also friability, surface roughness, and so 
on. In the 1990s, S-SMEDDS were usually in the form of 
SME capsules, SME solid dispersions and dry emulsions, 
but other solid SME dosage forms have emerged in recent 
years, such as SME pellets/tablets, SME microspheres/na-
noparticles and SME suppositories/implants. The merits of 
S-SMEDDS are as follows:
 – Spontaneous formation
 – Ease of manufacture
 – Thermodynamic stability and
 – Improved solubilization of bioactive materials
 – More consistent temporal profiles of drug absorption
 – Greater bioavailability
 – less drug need to be used
 – For many drugs taken by mouth
 – Faster release rates and it improve the drug acceptance 
by consumers
 – Selective drug targeting toward a specific absorption 
window in the GI tract and
 – Drug protection from the hostile environment in the gut
 – Thus, for lipophilic drug compounds that exhibit disso-
lution rate limited absorption
 – These systems may offer an improvement in the rate 
and extent of absorption and result in more reproduc-
ible blood time profiles
 – This may lower cost
Solidification techniques for transforming liquid/sem-
isolid SMEDDS to S-SMEDDS
Capsule filling with liquid and semisolid self-emulsifying 
formulations: Capsule filling is the simplest and the most 
common technology for the encapsulation of liquid or 
semisolid SE formulations for the oral route. For semisolid 
formulations, it is a four-step process:
i. heating of the semisolid excipient to at least 200°C above 
its melting point;
ii. Incorporation of the active substances (with stirring);
iii. Capsule filling with the molten mixture and
iv. Cooling to room temperature.
For liquid formulations, it involves a two-step process: fill-
ing of the formulation into the capsules followed by seal-
ing of the body and cap of the capsule, either by banding 
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or by microspray sealing.20 In parallel with the advances 
in capsule technology proceeding, liquid OROS® technol-
ogy has been designed for controlled delivery of insoluble 
drug substances or peptides. This system is based on os-
motic principles and is a liquid SME formulation system. 
It consists of an osmotic layer, which expands after coming 
into contact with water and pumps the drug formulation 
through an orifice in the hard or soft capsule.21 A primary 
consideration in capsule filling is the compatibility of the 
excipients with the capsule shell. The advantages of cap-
sule filling are simplicity of manufacturing; suitability for 
low-dose highly potent drugs and high drug loading (up to 
50% (w/w)) potential.
a) Spray drying
Essentially, this technique involves the preparation of a 
formulation by mixing lipids, surfactants, drug, solid car-
riers, and solubilization of the mixture before spray drying. 
The solubilized liquid formulation is then atomized into a 
spray of droplets. The droplets are introduced into a dry-
ing chamber, where the volatile phase (e.g. the water con-
tained in an emulsion) evaporates, forming dry particles 
under controlled temperature and airflow conditions. Such 
particles can be further prepared into tablets or capsules. 
The atomizer, the temperature, the most suitable airflow 
pattern and the drying chamber design are selected accord-
ing to the drying characteristics of the product and powder 
specification.22
b) Adsorption to solid carriers
Free flowing powders may be obtained from liquid SME 
formulations by adsorption to solid carriers. The adsorp-
tion process is simple and just involves addition of the liq-
uid formulation onto carriers by mixing in a blender. The 
resulting powder may then be filled directly into capsules 
or, alternatively, mixed with suitable excipients before com-
pression into tablets. A significant benefit of the adsorption 
technique is good content uniformity. A formulation of 
Liquid SMEDDS which is converted to Solid SMEDDS us-
ing maltodextrin as a solid carrier is represented in Fig. 2. 
SMEDDS can be adsorbed at high levels (up to 70% (w/w)) 
onto suitable carriers.23 Solid carriers can be micro porous 
inorganic substances, high surface-area colloidal inorganic 
adsorbent substances, cross-linked Polymers or Nanopar-
ticle adsorbents, for example, silica, silicates, magnesium 
trisilicate, magnesium hydroxide, talcum crospovidone, 
cross-linked sodium carboxymethyl cellulose and cross 
linked polymethyl methacrylate. Cross-linked polymers 
create a favorable environment to sustain drug dissolution 
and also assist in slowing down drug reprecipitation. Na-
noparticle adsorbents comprise porous silicon dioxide, car-
bon nanotubes, carbon nanohorns, fullerene, charcoal and 
bamboo charcoal.24
Fig. 2. Liquid SMEDDS versus Solid SMEDDS before and 
After Dilution with Water
c) Melt granulation
Melt granulation is a process in which powder agglomera-
tion is obtained through the addition of a binder that melts 
or softens at relatively low temperatures. As a ‘one-step’ 
operation, melt granulation offers several advantages com-
pared with conventional wet granulation, since the liquid 
addition and the subsequent drying phase are omitted. 
Moreover, it is also a good alternative to the use of solvent. 
The main parameters that control the granulation process 
are impeller speed, mixing time, binder particle size, and 
the viscosity of the binder. A wide range of solid and semi-
solid lipids can be applied as meltable binders. There into, 
Gelucire1, a family of vehicles derived from the mixtures of 
mono-/di-/tri-glycerides and polyethylene glycols (PEG) 
esters of fatty acids, is able to further increase the dissolu-
tion rate compared with PEG usually used before, probably 
owing to its SME property.25 Other lipid based excipients 
evaluated for melt granulation to create solid SMES in-
clude lecithin, partial glycerides, or polysorbates. The melt 
granulation process was usually used for adsorbing SMES 
(lipids, surfactants, and drugs) onto solid neutral carriers 
(mainly silica and magnesium alumina metasilicate).26, 27
d) Melt extrusion/extrusion Spheronization
Melt extrusion is a solvent-free process that allows high 
drug loading (60%), as well as content uniformity. Extru-
sion is a procedure of converting a raw material with plas-
tic properties into a product of uniform shape and density, 
by forcing it through a die under controlled temperature, 
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product flow, and pressure conditions.28 The size of the ex-
truder aperture will determine the approximate size of the 
resulting spheroids. The extrusion-spheronization process 
is commonly used in the pharmaceutical industry to make 
uniformly sized spheroids (pellets).
The extrusion–spheronization process requires the fol-
lowing steps: Dry mixing of the active ingredients and 
excipients to achieve a homogeneous powder; wet mass-
ing with binder; extrusion into a spaghetti-like extrudate; 
spheronization from the extrudate to spheroids of uniform 
size; drying; sifting to achieve the desired size distribution 
and coating (optional). In the wet masses comprising SMES 
(Polysorbate 80 and mono-/di-glycerides), lactose, water 
and MCC, the relative quantities of SMES and water had 
a significant effect on the extrusion force, size spread, dis-
integration time, and surface roughness of pellets. Studies 
suggested that the maximum quantity of this SMES that 
can be solidified by extrusion spheronization occupies 42% 
of the dry pellet weight.29 Generally, the higher the water 
level, the longer the disintegration time.30 The rheological 
properties of wet masses may be measured by an extru-
sion capillary. It has been shown that SMEs containing wet 
mass with a wide range of rheological characteristics can 
be processed, but a single rheological parameter cannot be 
used to provide complete characterization of how well it 
can be processed by extrusion-spheronization.31 Applying 
extrusion-spheronization, SME pellets of diazepam and 
progesterone and bi-layered cohesive SME pellets have 
been prepared.32, 33
Dosage form development of S-SMEDDS
Dry emulsions
Dry emulsions are powders from which emulsion spon-
taneously occurs in vivo or when exposed to an aqueous 
solution. Dry emulsions can be useful for further prepara-
tion of tablets and capsules. Dry emulsion formulations are 
typically prepared from oil/ water (O/W) emulsions con-
taining a solid carrier (lactose, maltodextrin, and so on) in 
the aqueous phase by rotary evaporation34, freeze-drying35 
or spray drying.36, 37 Myers and Shively obtained solid state 
glass emulsions in the form of dry ‘foam’ by rotary evapo-
ration, with heavy mineral oil and sucrose. Such emulsifi-
able glasses have the advantage of not requiring surfactant. 
In freeze-drying, a slow cooling rate and the addition of 
amorphous cryoprotectants have the best stabilizing ef-
fects, while heat treatment before thawing decreases the 
stabilizing effects. The technique of spray drying is more 
frequently used in preparation of dry emulsions.38 The 
O/W emulsion was formulated and then spray-dried to re-
move the aqueous phase. The most exciting finding in this 
field ought to be the newly developed enteric-coated dry 
emulsion formulation, which is potentially applicable for 
the oral delivery of peptide and protein drugs. This formu-
lation consisted of a surfactant, a vegetable oil, and a pH-
responsive polymer, with lyophilisation used.
Self-micron emulsifying capsules
After administration of capsules containing conventional 
liquid SME formulations, microemulsion droplets form 
and subsequently disperse in the GI tract to reach sites of 
absorption. However, if irreversible phase separation of the 
microemulsion occurs, an improvement of drug absorption 
cannot be expected. For handling this problem, sodium do-
decyl sulfate was added into the SME formulation.39 With 
the similar purpose, the supersaturable SMEDDS was de-
signed, using a small quantity of HPMC (or other polymers) 
in the formulation to prevent precipitation of the drug by 
generating and maintaining a supersaturated state in vivo. 
This system contains a reduced amount of a surfactant, 
thereby minimizing GI side effects.40, 41 Besides liquid fill-
ing, liquid SE ingredients also can be filled into capsules 
in a solid or semisolid state obtained by adding solid car-
riers (adsorbents, polymers, and so on). As an example, a 
solid PEG matrix can be chosen. The presence of solid PEG 
neither interfered with the solubility of the drug, nor did it 
interfere with the process of self-micro emulsification upon 
mixing with water.42, 43 Oral administration of SME capsules 
has been found to enhance patient compliance compared 
with the previously used parenteral route. For instance, 
low molecular weight heparin (LMWH) used for the treat-
ment of venous thromboembolism was clinically available 
only via the parenteral route. So, oral LMWH therapy was 
investigated by formulating it in hard capsules. LMWH 
was dispersed in SMEDDS and thereafter the mixture was 
solidified to powders using three kinds of adsorbents: mi-
cro porous calcium silicate; magnesium aluminium silicate 
and silicon dioxide. Eventually these solids were filled into 
hard capsules.44 In another study, such adsorbents were 
also applied to prepare SME tablets of gentamicin that, in 
clinical use, was limited to administration as injectable or 
topical dosage forms.
Self- micron emulsifying sustained/controlled-release tablets
Combinations of lipids and surfactants have presented 
great potential of preparing SME tablets that have been 
widely researched. In order to reduce significantly the 
amount of solidifying excipients required for transforma-
tion of SEDDS into solid dosage forms, a gelled SMEDDS 
has been developed, colloidal silicon dioxide (Aerosil 200) 
was selected as a gelling agent for the oil-based systems, 
which served the dual purpose of reducing the amount of 
required solidifying excipients and aiding in slowing down 
of the drug release. SE tablets are of great utility in obviat-
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ing adverse effect for example; SE tablets may increase its 
penetration efficacy through the GI mucosal membranes, 
potentially reducing GI bleeding. The resultant SME tab-
lets consistently maintained a higher active ingredient 
concentration in blood plasma over the same time frame 
compared with a non-emulsifying tablet.45 The newest ad-
vance in the research field of SME tablet is the SME osmotic 
pump tablet, where the elementary osmotic pump system 
was chosen as the carrier of SMES. This system has out-
standing features such as stable plasma concentrations and 
controllable drug release rate, allowing a bioavailability of 
156.78% relative to commercial carvedilol tablets.46
Self- micro emulsifying sustained/controlled-release pellets
Pellets, as a multiple unit dosage form, possess many ad-
vantages over conventional solid dosage forms, such as 
flexibility of manufacture, reducing intrasubject and inter-
subject variability of plasma profiles and minimizing GI ir-
ritation without lowering drug bioavailability.47 Thus, it is 
very appealing to combine the advantages of pellets with 
those of SMEDDS by SME pellets.
Self- micron emulsifying solid dispersions
Although solid dispersions could increase the dissolution 
rate and bioavailability of poorly water-soluble drugs, 
some manufacturing difficulties and stability problems ex-
isted. Excipients have the potential to increase further the 
absorption of poorly water-soluble drugs relative to previ-
ously used PEG solid dispersions and may also be filled 
directly into hard gelatin capsules in the molten state, thus 
obviating the former requirement for milling and blending 
before filling. SME excipients like Gelucire1 44/14, Gelu-
cire150/02, Labrasol1, Transcutol1 and TPGS (tocopheryl 
polyethylene glycol 1000 succinate) have been widely used 
in this field.48-51
Self- micron emulsifying suppositories
Some investigators proved that S-SMEDDS could increase 
not only GI adsorption but also rectal/vaginal adsorption.52 
For example Glycyrrhizin, which is given by the oral route, 
barely achieves therapeutic plasma concentrations, can ob-
tain satisfactory therapeutic levels for chronic hepatic dis-
eases by either vaginal or rectal SME suppositories.
Self- micron emulsifying implants
Research into SME implants has greatly enhanced the util-
ity and application of S-SMEDDS. As an example, 1,3bis 
(2-chloroethyl)-1- nitrosourea is a chemotherapeutic agent 
used to treat malignant brain tumours. However, its effec-
tiveness was hindered by its short half-life. In order to en-
hance its stability compared with that released from poly 
(d, l-lactide-co-glycolide) (PLGA) wafer implants, SMES 
was formulated. Such wafers had higher in vitro antitumor 
activity and were less susceptible to hydrolysis.53
Table 3. Bioavailability enhancement of some drugs using micron emulsion technology
S. No. Drug Category System
1 Paclitaxel Anticancer SMEDDS
2 Fenofibrate, Fluvastatin Antihyperlipidemic SMEDDS
3 Rapamycin, Cyclosporin Immunosuppresive SMEDDS
4 Nifedipine Antihypertensive SMEDDS
5 Ibuprofen, Naproxen Analgesic SMEDDS
6 Tipranavir Anti- HIV SMEDDS
7 Progesterone, Hormones SMEDDS
8 Vitamins (A,D,E,K) Nutritional supplement SMEDDS
9 Acyclovir Antiviral SMEDDS
10 Melatonin Immunomodulatory SMEDDS
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CONCLUSIONS
SMEDDS are a promising approach for the formulation 
of drugs with poor aqueous solubility. The oral delivery 
of hydrophobic drugs can be made possible by SMEDDS, 
which have been shown to substantially improve oral Bio-
availability. As mentioned above, numerous studies have 
confirmed that SMEDDS substantially improved solubil-
ity/dissolution, absorption and bioavailability of poorly 
water-soluble drugs; some of such drugs are listed in Table 
3. As improvements or alternatives of conventional liquid 
SMEDDS, S-SMEDDS are superior in reducing production 
cost, simplifying industrial manufacture, and improving 
stability as well as patient compliance. Most importantly, S-
SMEDDS are very flexible to develop various solid dosage 
forms for oral and parenteral administration. Moreover, GI 
irritation is avoidable and controlled/sustained release of 
drug is achievable. There is still a long way to go, however, 
before more solid SME dosage forms (except for SME cap-
sules) appear on the market. Because there exist some fields 
of S-SMEDDS to be further exploited, such as studies about 
human bioavailability and correlation of in vitro/in vivo.
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